Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
August 08, 2017 08:00 ET
|
Esperion Therapeutics, Inc.
– Phase 3 Enrollment Progress Supports NDA Submissions for LDL-C Lowering Indications for Bempedoic Acid / Ezetimibe Combination Pill and Bempedoic Acid by the First Quarter 2019 –– Conference Call...
Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
August 08, 2017 07:30 ET
|
Esperion Therapeutics, Inc.
– 1002-038 Study Meets Primary Endpoint With a Robust 64% LDL-C Lowering Efficacy –– Clinically Relevant 48% hsCRP Reduction –– The Combination Therapy Was Observed to be Safe and Well-Tolerated ––...
Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results
August 02, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Conference Call and Webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern Time – ANN ARBOR, Mich., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
July 26, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 26, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
June 26, 2017 16:05 ET
|
Esperion Therapeutics, Inc.
– Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of...
Esperion to Present at the JMP Securities 2017 Life Sciences Conference
June 14, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Presentation and Webcast on Wednesday, June 21, 2017 at 10:00 a.m. Eastern Time ANN ARBOR, Mich., June 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management...
Esperion to Present at the Jefferies 2017 Global Healthcare Conference
May 31, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Presentation on Wednesday, June 7, 2017 at 10:30 a.m. Eastern Time ANN ARBOR, Mich., May 31, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused...
Esperion Provides Update on Common Stock Trading Activity
May 22, 2017 08:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 22, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
May 19, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Tuesday, May 23, 2017 at 9:00 a.m. Eastern Time ANN ARBOR, Mich., May 19, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 12, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat on Wednesday, May 17, 2017 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time ANN ARBOR, Mich., May 12, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...